Form 4: Helius Medical Technologies Director Acquires Stock Options

Director Sherrie L. Perkins of Helius Medical Technologies acquired 10,732 stock options on January 6, 2025, under the company's 2022 Equity Incentive Plan.

Summary

• Sherrie L. Perkins, a director at Helius Medical Technologies, was granted 10,732 stock options on January 6, 2025.
• These options were granted under the company's 2022 Equity Incentive Plan.
• The exercise price of the options is $0.7292 per share.
• 50% of the options vested immediately upon grant.
• The remaining 50% of the options will vest in four equal quarterly installments starting on March 31, 2025.
• Vesting is contingent upon the director's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to directors, which is generally viewed positively as it aligns interests. There are no indications of negative news or concerns.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If the director leaves the company before all options vest, they may forfeit the unvested portion.

Future Outlook

The remaining 50% of the options will vest in four equal quarterly installments starting on March 31, 2025, subject to the director's continued service.

Industry Context

Stock option grants are a common practice in the technology and medical device industries to incentivize and retain key personnel, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and executives in publicly traded companies, particularly in the technology and medical device sectors.
• The vesting schedule of 50% immediately and the remainder quarterly is a fairly typical structure to ensure continued service.
• Companies like Medtronic and Boston Scientific also use similar equity-based compensation plans for their directors and executives.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.
• The vesting schedule encourages the director's continued service, which benefits the company and its stakeholders.

Key Dates

Keywords

stock options, equity incentive plan, director, vesting, Helius Medical Technologies, HSDT